E. Frei, . Iii, C. Cucchi, A. Rosowsky, R. Tantravahi et al., Alkylating agent resistance: in vitro studies with human cell lines., Proceedings of the National Academy of Sciences, vol.82, issue.7, pp.2158-2162, 1985.
DOI : 10.1073/pnas.82.7.2158

V. Devita and P. Schein, The Use of Drugs in Combination for the Treatment of Cancer, New England Journal of Medicine, vol.288, issue.19, pp.998-1006, 1905.
DOI : 10.1056/NEJM197305102881905

I. Motabi and J. Dipersio, Advances in stem cell mobilization, Blood Reviews, vol.26, issue.6, pp.267-278, 2012.
DOI : 10.1016/j.blre.2012.09.003

H. Duong, B. Savani, E. Copelan, S. Devine, L. Costa et al., Peripheral Blood Progenitor Cell Mobilization for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation, Biology of Blood and Marrow Transplantation, vol.20, issue.9, pp.1262-1273, 2014.
DOI : 10.1016/j.bbmt.2014.05.003

E. Huyghe, P. Plante, and P. Thonneau, Testicular Cancer Variations in Time and Space in Europe, European Urology, vol.51, issue.3, pp.621-628, 2007.
DOI : 10.1016/j.eururo.2006.08.024

V. Reuter, Origins and molecular biology of testicular germ cell tumors, Modern Pathology, vol.81, issue.2, pp.51-60, 2005.
DOI : 10.1038/modpathol.3800309

J. Classen, R. Souchon, T. Hehr, and M. Bamberg, Treatment of early stage testicular seminoma, Journal of Cancer Research and Clinical Oncology, vol.127, issue.8, pp.475-481, 2001.
DOI : 10.1007/s004320100243

M. Shelley, K. Burgon, and M. Mason, Treatment of testicular germ-cell cancer: a cochrane evidence-based systematic review, Cancer Treatment Reviews, vol.28, issue.5, pp.237-253, 2002.
DOI : 10.1016/S0305-7372(02)00059-2

G. Bosl and R. Motzer, Testicular Germ-Cell Cancer, New England Journal of Medicine, vol.337, issue.4, pp.242-253, 1997.
DOI : 10.1056/NEJM199707243370406

N. Atkin and M. Baker, i(12p): Specific chromosomal marker in seminoma and malignant teratoma of the testis?, Cancer Genetics and Cytogenetics, vol.10, issue.2, pp.199-204, 1983.
DOI : 10.1016/0165-4608(83)90125-5

A. Sandberg, A. Meloni, and R. Suijkerbuijk, Reviews of Chromosome Studies in Urological Tumors. III. Cytogenetics and Genes in Testicular Tumors, The Journal of Urology, vol.155, issue.5, pp.1531-1556, 1996.
DOI : 10.1016/S0022-5347(01)66124-X

L. Looijenga, G. Zafarana, B. Grygalewicz, B. Summersgill, M. Debiec-rychter et al., Role of gain of 12p in germ cell tumour development, APMIS, vol.295, issue.5552, pp.161-171, 2003.
DOI : 10.1038/35057174

J. Korkola, J. Houldsworth, R. Chadalavada, A. Olshen, D. Dobrzynski et al., Down-Regulation of Stem Cell Genes, Including Those in a 200-kb Gene Cluster at 12p13.31, Is Associated with In vivo Differentiation of Human Male Germ Cell Tumors, Cancer Research, vol.66, issue.2, pp.820-827, 1158.
DOI : 10.1158/0008-5472.CAN-05-2445

M. Mostert, A. Verkerk, M. Van-de-pol, J. Heighway, P. Marynen et al., Identification of the critical region of 12p over-representation in testicular germ cell tumors of adolescents and adults, Oncogene, vol.16, issue.20, pp.2617-2627, 1998.
DOI : 10.1038/sj.onc.1201787

N. Goddard, A. Mcintyre, B. Summersgill, D. Gilbert, S. Kitazawa et al., KIT and RAS signalling pathways in testicular germ cell tumours: new data and a review of the literature, International Journal of Andrology, vol.154, issue.1, pp.337-348, 2007.
DOI : 10.1038/sj.onc.1207011

L. Einhorn and J. Donohue, Cis-Diamminedichloroplatinum, Vinblastine, and Bleomycin Combination Chemotherapy in Disseminated Testicular Cancer, Annals of Internal Medicine, vol.87, issue.3, pp.293-298, 1977.
DOI : 10.7326/0003-4819-87-3-293

D. Feldman, G. Bosl, J. Sheinfeld, and R. Motzer, Medical Treatment of Advanced Testicular Cancer, JAMA, vol.299, issue.6, pp.672-684, 2008.
DOI : 10.1001/jama.299.6.672

J. Masters, E. Osborne, M. Walker, and C. Parris, Hypersensitivity of human testis-tumour cell lines to chemotherapeutic drugs, International Journal of Cancer, vol.79, issue.2, pp.340-346, 1993.
DOI : 10.1002/ijc.2910530228

R. Huddart, J. Titley, D. Robertson, G. Williams, A. Horwich et al., Programmed cell death in response to chemotherapeutic agents in human germ cell tumour lines, European Journal of Cancer, vol.31, issue.5
DOI : 10.1016/0959-8049(95)00047-M

H. Peng, D. Hogg, D. Malkin, D. Bailey, B. Gallie et al., Mutations of the p53 gene do not occur in testis cancer, Cancer Res, vol.53, pp.3574-3578, 1993.

S. Lutzker, P53 tumour suppressor gene and germ cell neoplasia, APMIS, vol.150, issue.1-6, pp.85-89, 1998.
DOI : 10.1111/j.1699-0463.1998.tb01323.x

S. Lutzker, R. Mathew, and D. Taller, A p53 dose-response relationship for sensitivity to DNA damage in isogenic teratocarcinoma cells, Oncogene, vol.20, issue.23, pp.2982-2986, 2001.
DOI : 10.1038/sj.onc.1204394

J. Kerley-hamilton, A. Pike, N. Li, J. Direnzo, and M. Spinella, A p53-dominant transcriptional response to cisplatin in testicular germ cell tumor-derived human embyronal carcinoma, Oncogene, vol.35, issue.40, pp.6090-6100, 2005.
DOI : 10.1084/jem.182.2.367

M. Gutekunst, M. Oren, A. Weilbacher, M. Dengler, C. Markwardt et al., p53 Hypersensitivity Is the Predominant Mechanism of the Unique Responsiveness of Testicular Germ Cell Tumor (TGCT) Cells to Cisplatin, PLoS ONE, vol.69, issue.2, p.19198, 2011.
DOI : 10.1371/journal.pone.0019198.s006

J. Bartkova, R. Meyts, E. Skakkebaek, N. Lukas, J. Bartek et al., Deregulation of the G1/S-phase control in human testicular germ cell tumours, APMIS, vol.2, issue.1, pp.252-265, 2003.
DOI : 10.1038/sj.onc.1204254

C. Welsh, R. Day, C. Mcgurk, J. Masters, R. Wood et al., Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines, International Journal of Cancer, vol.10, issue.3, pp.352-361, 2004.
DOI : 10.1002/ijc.20134

A. Eastman, Reevaluation of interaction of cis-dichloro(ethylenediamine)platinum(II) with DNA, Biochemistry, vol.25, issue.13, pp.3912-3915, 1986.
DOI : 10.1021/bi00361a026

P. Mchugh, V. Spanswick, and J. Hartley, Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance, The Lancet Oncology, vol.2, issue.8, pp.483-490, 2001.
DOI : 10.1016/S1470-2045(01)00454-5

B. Koberle, V. Roginskaya, K. Zima, J. Masters, and R. Wood, Elevation of XPA protein level in testis tumor cells without increasing resistance to cisplatin or UV radiation, Molecular Carcinogenesis, vol.265, issue.8, pp.580-586, 2008.
DOI : 10.1002/mc.20418

S. Usanova, A. Piee-staffa, U. Sied, J. Thomale, A. Schneider et al., Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression, Molecular Cancer, vol.9, issue.1, pp.248-258, 2010.
DOI : 10.1186/1476-4598-9-248

K. Ferry, T. Hamilton, and S. Johnson, Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells, Biochemical Pharmacology, vol.60, issue.9, pp.1305-1313, 2000.
DOI : 10.1016/S0006-2952(00)00441-X

B. Koberle, M. Tomicic, S. Usanova, and B. Kaina, Cisplatin resistance: Preclinical findings and clinical implications, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, vol.1806, issue.2, pp.172-182, 2010.
DOI : 10.1016/j.bbcan.2010.07.004

F. Cavallo, D. Feldman, and M. Barchi, Revisiting DNA damage repair, p53-mediated apoptosis and cisplatin sensitivity in germ cell tumors, The International Journal of Developmental Biology, vol.57, issue.2-3-4, pp.273-280, 2013.
DOI : 10.1387/ijdb.130135mb

P. Andrews, Retinoic acid induces neuronal differentiation of a cloned human embryonal carcinoma cell line in vitro, Developmental Biology, vol.103, issue.2, pp.285-293, 1984.
DOI : 10.1016/0012-1606(84)90316-6

H. Timmer-bosscha, E. De-vries, C. Meijer, J. Oosterhuis, and N. Mulder, Differential effects of all-trans -retinoic acid, docosahexaenoic acid, and hexadecylphosphocholine on cisplatin-induced cytotoxicity and apoptosis in a cisplantin-sensitive and resistant human embryonal carcinoma cell line, Cancer Chemotherapy and Pharmacology, vol.41, issue.6, pp.469-476, 1998.
DOI : 10.1007/s002800050769

F. Cavallo, G. Graziani, C. Antinozzi, D. Feldman, J. Houldsworth et al., Reduced Proficiency in Homologous Recombination Underlies the High Sensitivity of Embryonal Carcinoma Testicular Germ Cell Tumors to Cisplatin and Poly (ADP-Ribose) Polymerase Inhibition, PLoS ONE, vol.43, issue.12, p.51563, 2012.
DOI : 10.1371/journal.pone.0051563.s007

R. Koster, H. Timmer-bosscha, R. Bischoff, J. Gietema, and S. De-jong, Disruption of the MDM2???p53 interaction strongly potentiates p53-dependent apoptosis in cisplatin-resistant human testicular carcinoma cells via the Fas/FasL pathway, Cell Death and Disease, vol.41, issue.4, p.148, 2011.
DOI : 10.1038/cddis.2011.33

L. Einhorn, Treatment of testicular cancer: a new and improved model., Journal of Clinical Oncology, vol.8, issue.11, pp.1777-1781, 1990.
DOI : 10.1200/JCO.1990.8.11.1777

H. Schmoll, R. Souchon, S. Krege, P. Albers, J. Beyer et al., European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG), Annals of Oncology, vol.15, issue.9
DOI : 10.1093/annonc/mdh301
URL : https://hal.archives-ouvertes.fr/hal-00281486

G. Mead, M. Cullen, R. Huddart, P. Harper, G. Rustin et al., A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial, British Journal of Cancer, vol.21, issue.2, pp.178-184, 2005.
DOI : 10.1002/(SICI)1097-0142(19980401)82:7<1381::AID-CNCR23>3.0.CO;2-1

G. Kondagunta, J. Bacik, A. Donadio, D. Bajorin, S. Marion et al., Combination of Paclitaxel, Ifosfamide, and Cisplatin Is an Effective Second-Line Therapy for Patients With Relapsed Testicular Germ Cell Tumors, Journal of Clinical Oncology, vol.23, issue.27, pp.6549-6555, 2005.
DOI : 10.1200/JCO.2005.19.638

J. Mccaffrey, M. Mazumdar, D. Bajorin, G. Bosl, V. Vlamis et al., Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival., Journal of Clinical Oncology, vol.15, issue.7, pp.2559-2563, 1997.
DOI : 10.1200/JCO.1997.15.7.2559

R. Motzer, M. Mazumdar, S. Gulati, D. Bajorin, P. Lyn et al., Phase II Trial of High-Dose Carboplatin and Etoposide With Autologous Bone Marrow Transplantation in First-Line Therapy for Patients With Poor-Risk Germ Cell Tumors, JNCI Journal of the National Cancer Institute, vol.85, issue.22
DOI : 10.1093/jnci/85.22.1828

R. Motzer, M. Mazumdar, D. Bajorin, G. Bosl, P. Lyn et al., High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors., Journal of Clinical Oncology, vol.15, issue.7
DOI : 10.1200/JCO.1997.15.7.2546

C. Bokemeyer, C. Kollmannsberger, C. Meisner, A. Harstrick, J. Beyer et al., First-Line High-Dose Chemotherapy Compared With Standard-Dose PEB/VIP Chemotherapy in Patients With Advanced Germ Cell Tumors: A Multivariate and Matched-Pair Analysis, Journal of Clinical Oncology, vol.17, issue.11, pp.3450-3456, 1999.
DOI : 10.1200/JCO.1999.17.11.3450

H. Schmoll, C. Kollmannsberger, B. Metzner, J. Hartmann, N. Schleucher et al., Long-Term Results of First-Line Sequential High-Dose Etoposide, Ifosfamide, and Cisplatin Chemotherapy Plus Autologous Stem Cell Support for Patients With Advanced Metastatic Germ Cell Cancer: An Extended Phase I/II Study of the German Testicular Cancer Study Group, Journal of Clinical Oncology, vol.21, issue.22, pp.4083-4091, 2003.
DOI : 10.1200/JCO.2003.09.035

C. Bokemeyer, N. Schleucher, B. Metzner, M. Thomas, R. O. Schmoll et al., First-line sequential high-dose VIP chemotherapy with autologous transplantation for patients with primary mediastinal nonseminomatous germ cell tumours: a prospective trial, British Journal of Cancer, vol.99, issue.1, pp.29-35, 2003.
DOI : 10.1023/A:1008225129682

J. Hartmann, T. Gauler, B. Metzner, A. Gerl, J. Casper et al., Phase I/II Study of Sequential Dose-Intensified Ifosfamide, Cisplatin, and Etoposide Plus Paclitaxel As Induction Chemotherapy for Poor Prognosis Germ Cell Tumors by the German Testicular Cancer Study Group, Journal of Clinical Oncology, vol.25, issue.36, pp.5742-5747, 2007.
DOI : 10.1200/JCO.2007.11.9099

J. Droz, A. Kramar, P. Biron, J. Pico, P. Kerbrat et al., Failure of High-Dose Cyclophosphamide and Etoposide Combined with Double-Dose Cisplatin and Bone Marrow Support in Patients with High-Volume Metastatic Nonseminomatous Germ-Cell Tumours: Mature Results of a Randomised Trial, European Urology, vol.51, issue.3, pp.739-746, 2007.
DOI : 10.1016/j.eururo.2006.10.035

R. Motzer, C. Nichols, K. Margolin, J. Bacik, P. Richardson et al., Phase III Randomized Trial of Conventional-Dose Chemotherapy With or Without High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Rescue As First-Line Treatment for Patients With Poor-Prognosis Metastatic Germ Cell Tumors, Journal of Clinical Oncology, vol.25, issue.3, pp.247-256, 2007.
DOI : 10.1200/JCO.2005.05.4528

G. Daugaard, I. Skoneczna, N. Aass, R. De-wit, D. Santis et al., A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974), Annals of Oncology, vol.22, issue.5, pp.1054-1061, 2011.
DOI : 10.1093/annonc/mdq575

A. Lorch, C. Bascoul-mollevi, A. Kramar, L. Einhorn, A. Necchi et al., Conventional-Dose Versus High-Dose Chemotherapy As First Salvage Treatment in Male Patients With Metastatic Germ Cell Tumors: Evidence From a Large International Database, Journal of Clinical Oncology, vol.29, issue.16, pp.2178-2184, 2011.
DOI : 10.1200/JCO.2010.32.6678

A. Lorch, J. Beyer, C. Bascoul-mollevi, A. Kramar, L. Einhorn et al., Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy, J Clin Oncol, vol.28, pp.4906-4911, 2010.

A. Lorch, A. Kleinhans, A. Kramar, C. Kollmannsberger, J. Hartmann et al., Sequential Versus Single High-Dose Chemotherapy in Patients With Relapsed or Refractory Germ Cell Tumors: Long-Term Results of a Prospective Randomized Trial, Journal of Clinical Oncology, vol.30, issue.8, pp.800-805, 2012.
DOI : 10.1200/JCO.2011.38.6391

D. Feldman, J. Sheinfeld, D. Bajorin, P. Fischer, S. Turkula et al., TI-CE High-Dose Chemotherapy for Patients With Previously Treated Germ Cell Tumors: Results and Prognostic Factor Analysis, Journal of Clinical Oncology, vol.28, issue.10, pp.1706-1713, 2010.
DOI : 10.1200/JCO.2009.25.1561

J. Beyer, P. Albers, R. Altena, J. Aparicio, C. Bokemeyer et al., Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer, Annals of Oncology, vol.24, issue.4, pp.878-888, 2013.
DOI : 10.1093/annonc/mds579

L. Einhorn, S. Williams, A. Chamness, M. Brames, S. Perkins et al., High-Dose Chemotherapy and Stem-Cell Rescue for Metastatic Germ-Cell Tumors, New England Journal of Medicine, vol.357, issue.4, pp.340-348, 2007.
DOI : 10.1056/NEJMoa067749

J. Pico, G. Rosti, A. Kramar, H. Wandt, V. Koza et al., A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours, Annals of Oncology, vol.16, issue.7, pp.1152-1159, 2005.
DOI : 10.1093/annonc/mdi228

D. Feldman, R. Huddart, E. Hall, J. Beyer, and T. Powles, Is High Dose Therapy Superior to Conventional Dose Therapy as Initial Treatment for Relapsed Germ Cell Tumors? The TIGER Trial, Journal of Cancer, vol.2, pp.374-377, 2011.
DOI : 10.7150/jca.2.374

C. Nichols, G. Tricot, S. Williams, K. Van-besien, P. Loehrer et al., Dose-intensive chemotherapy in refractory germ cell cancer--a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation., Journal of Clinical Oncology, vol.7, issue.7, pp.932-939, 1989.
DOI : 10.1200/JCO.1989.7.7.932

W. Siegert, J. Beyer, I. Strohscheer, H. Baurmann, H. Oettle et al., High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group., Journal of Clinical Oncology, vol.12, issue.6, pp.1223-1231, 1994.
DOI : 10.1200/JCO.1994.12.6.1223

J. Lotz, B. Bui, F. Gomez, C. Theodore, C. A. Fizazi et al., Sequential high-dose chemotherapy protocol for relapsed poor prognosis germ cell tumors combining two mobilization and cytoreductive treatments followed by three high-dose chemotherapy regimens supported by autologous stem cell transplantation. Results of the phase II multicentric TAXIF trial, Annals of Oncology, vol.16, issue.3, pp.411-418, 2005.
DOI : 10.1093/annonc/mdi087

F. Selle, S. Wittnebel, P. Biron, G. Gravis, G. Roubaud et al., A phase II trial of high-dose chemotherapy (HDCT) supported by hematopoietic stem-cell transplantation (HSCT) in germ-cell tumors (GCTs) patients failing cisplatin-based chemotherapy: the Multicentric TAXIF II study, Annals of Oncology, vol.25, issue.9
DOI : 10.1093/annonc/mdu198

J. Beyer, A. Kramar, R. Mandanas, W. Linkesch, A. Greinix et al., High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables., Journal of Clinical Oncology, vol.14, issue.10, pp.2638-2645, 1996.
DOI : 10.1200/JCO.1996.14.10.2638

W. Bentas, W. Beecken, W. Glienke, J. Binder, and H. Schuldes, Serum levels of basic fibroblast growth factor reflect disseminated disease in patients with testicular germ cell tumors, Urol Res, vol.30, pp.390-393, 2003.

S. Fukuda, T. Shirahama, Y. Imazono, T. Tsushima, H. Ohmori et al., Expression of vascular endothelial growth factor in patients with testicular germ cell tumors as an indicator of metastatic disease, AID-CNCR15.3.0.CO, pp.1323-13301097, 1999.

A. Jones, C. Fujiyama, K. Turner, S. Fuggle, D. Cranston et al., Angiogenesis and lymphangiogenesis in stage 1 germ cell tumours of the testis, BJU International, vol.153, issue.1, pp.80-86, 2000.
DOI : 10.1046/j.1464-410x.2000.00660.x

W. Voigt, T. Kegel, G. Maher, K. Jordan, L. Muller et al., Bevacizumab plus high-dose ifosfamide, etoposide and carboplatin (HD-ICE) as third-line salvage chemotherapy induced an unexpected dramatic response in highly platinum refractory germ-cell cancer, Annals of Oncology, vol.17, issue.3, pp.531-533, 2006.
DOI : 10.1093/annonc/mdj028

Y. Nieto, S. Tu, R. Jones, N. Tannir, R. Bassett et al., Phase 2 trial of bevacizumab (BEV)/highdose chemotherapy (HDC) with autologous stem-cell transplant (ASCT) for refractory germ-cell tumors (GCT)

W. Peters, M. Ross, J. Vredenburgh, B. Meisenberg, L. Marks et al., High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer., Journal of Clinical Oncology, vol.11, issue.6, pp.1132-1143, 1993.
DOI : 10.1200/JCO.1993.11.6.1132

R. Weiss, R. Rifkin, F. Stewart, R. Theriault, L. Williams et al., High-dose chemotherapy for high-risk primary breast cancer: an on-site review of the Bezwoda study, The Lancet, vol.355, issue.9208, pp.999-1003, 2000.
DOI : 10.1016/S0140-6736(00)90024-2

D. Berry, N. Ueno, M. Johnson, X. Lei, J. Caputo et al., High-Dose Chemotherapy With Autologous Stem-Cell Support As Adjuvant Therapy in Breast Cancer: Overview of 15 Randomized Trials, Journal of Clinical Oncology, vol.29, issue.24, pp.3214-3223, 2011.
DOI : 10.1200/JCO.2010.32.5910

D. Berry, N. Ueno, M. Johnson, X. Lei, J. Caputo et al., High-Dose Chemotherapy With Autologous Hematopoietic Stem-Cell Transplantation in Metastatic Breast Cancer: Overview of Six Randomized Trials, Journal of Clinical Oncology, vol.29, issue.24, pp.3224-3231, 2011.
DOI : 10.1200/JCO.2010.32.5936

J. Lotz, H. Cure, M. Janvier, B. Asselain, F. Morvan et al., High-dose chemotherapy with haematopoietic stem cell transplantation for metastatic breast cancer patients: final results of the French multicentric randomised CMA/PEGASE 04 protocol, European Journal of Cancer, vol.41, issue.1, pp.71-80, 2005.
DOI : 10.1016/j.ejca.2004.09.006

M. Martino, A. Bottini, G. Rosti, D. Generali, S. Secondino et al., Critical issues on high-dose chemotherapy with autologous hematopoietic progenitor cell transplantation in breast cancer patients, Expert Opinion on Biological Therapy, vol.26, issue.20, pp.1505-1515, 2012.
DOI : 10.1056/NEJMoa032290

P. Stiff, R. Bayer, C. Kerger, R. Potkul, D. Malhotra et al., High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: a multivariate analysis of survival for 100 consecutively treated patients., Journal of Clinical Oncology, vol.15, issue.4, pp.1309-1317, 1997.
DOI : 10.1200/JCO.1997.15.4.1309

J. Lotz, P. Pautier, F. Selle, P. Viens, M. Fabbro et al., Phase I study of high-dose topotecan with haematopoietic stem cell support in the treatment of ovarian carcinomas: the ITOV 01 protocol, Bone Marrow Transplantation, vol.36, issue.7, pp.669-675, 2006.
DOI : 10.1038/sj.bmt.1705310

J. Lotz, P. Pautier, F. Selle, M. Fabbro, P. Viens et al., A phase I study combining high-dose (HD) topotecan (TPC) plus cyclophosphamide (CPM) with blood stem cells support in poor prognosis ovarian carcinoma (OC): The ITOV 01bis protocol, ASCO Annual Meeting Proceedings, p.16061, 2007.

R. Sabatier, A. Goncalves, F. Bertucci, M. Capiello, F. Rousseau et al., Are there candidates for high-dose chemotherapy in ovarian carcinoma?, Journal of Experimental & Clinical Cancer Research, vol.31, issue.1, pp.87-97, 2012.
DOI : 10.1056/NEJMoa1103799
URL : https://hal.archives-ouvertes.fr/inserm-00765646

V. Mobus, H. Wandt, N. Frickhofen, C. Bengala, K. Champion et al., Phase III Trial of High-Dose Sequential Chemotherapy With Peripheral Blood Stem Cell Support Compared With Standard Dose Chemotherapy for First-Line Treatment of Advanced Ovarian Cancer: Intergroup Trial of the AGO-Ovar/AIO and EBMT, Journal of Clinical Oncology, vol.25, issue.27, pp.4187-4193, 2007.
DOI : 10.1200/JCO.2006.09.7527

C. Papadimitriou, U. Dafni, A. Anagnostopoulos, G. Vlachos, Z. Voulgaris et al., High-dose melphalan and autologous stem cell transplantation as consolidation treatment in patients with chemosensitive ovarian cancer: results of a single-institution randomized trial, Bone Marrow Transplantation, vol.23, issue.6, pp.547-554, 2008.
DOI : 10.1002/1097-0142(19841201)54:2+<2706::AID-CNCR2820541417>3.0.CO;2-L

H. Lazarus, M. Reed, T. Spitzer, M. Rabaa, and J. Blumer, High-dose iv thiotepa and cryopreserved autologous bone marrow transplantation for therapy of refractory cancer, Cancer Treat Rep, vol.71, pp.689-695, 1987.

N. Kroger, A. Zander, G. Martinelli, P. Ferrante, J. Moraleda et al., Low incidence of secondary myelodysplasia and acute myeloid leukemia after high-dose chemotherapy as adjuvant therapy for breast cancer patients: a study by the Solid Tumors Working Party of the European Group for Blood and Marrow Transplantation, Annals of Oncology, vol.14, issue.4
DOI : 10.1093/annonc/mdg161

A. Shimoni and M. Korbling, Tumor cell contamination in re-infused stem cell autografts: does it have clinical significance?, Critical Reviews in Oncology/Hematology, vol.41, issue.2, pp.241-250, 2002.
DOI : 10.1016/S1040-8428(01)00160-3

S. Rodenhuis, M. Bontenbal, Q. Van-hoesel, W. Smit, M. Nooij et al., Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer, Annals of Oncology, vol.17, issue.4, pp.588-596, 2006.
DOI : 10.1093/annonc/mdl001

O. Gluz, U. Nitz, N. Harbeck, E. Ting, R. Kates et al., Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial, Annals of Oncology, vol.19, issue.5, pp.861-870, 2008.
DOI : 10.1093/annonc/mdm551

O. Rick, C. Bokemeyer, J. Beyer, J. Hartmann, N. Schwella et al., Salvage Treatment With Paclitaxel, Ifosfamide, and Cisplatin Plus High-Dose Carboplatin, Etoposide, and Thiotepa Followed by Autologous Stem-Cell Rescue in Patients With Relapsed or Refractory Germ Cell Cancer, Journal of Clinical Oncology, vol.19, issue.1, pp.81-88, 2001.
DOI : 10.1200/JCO.2001.19.1.81

D. Giorgi, U. Demirer, T. Wandt, H. Taverna, C. Siegert et al., Second-line high-dose chemotherapy in patients with mediastinal and retroperitoneal primary nonseminomatous germ cell tumors: the EBMT experience

A. Lorch, A. Neubauer, M. Hackenthal, A. Dieing, J. Hartmann et al., High-dose chemotherapy (HDCT) as second-salvage treatment in patients with multiple relapsed or refractory germ-cell tumors, Annals of Oncology, vol.21, issue.4, pp.820-825, 2010.
DOI : 10.1093/annonc/mdp366